Dr. Amy Chappell joined the BioVie Board of Directors in 2025. She currently serves as Chief Medical Officer of Solaxa Inc., where her leadership is helping the company advance therapies for ataxia and nerve repair. During her tenure as Chief Medical Officer of Eliem Therapeutics, she guided programs in epilepsy and mood disorders and helped lead the company through a successful initial public offering (IPO). Previously, she spent more than 25 years at Eli Lilly & Co., contributing to multiple Food and Drug Administration (FDA) approvals, including Cymbalta® for fibromyalgia and musculoskeletal pain. Dr. Chappell is a Fellow of the American Academy of Neurology, holds numerous patents, and has authored over 100 peer-reviewed publications. She earned her BA from Antioch College and her MD from Indiana University School of Medicine.